Fig. 1

RAS-mutant MM cell lines show variable sensitivity to trametinib. a. RAS mutation status and dependency in multiple myeloma cell lines (www.depmap.org). b. A panel of multiple myeloma cell lines was exposed to a titration of trametinib or dexamethasone for 5 d. Cell proliferation was assessed by CellTiter-Blue assay. Data are representative of 3 independent experiments carried out in triplicate. c. MM.1S and MM.1R cells were treated with a titration of trametinib for 24 h and cell lysates analysed by Western blotting for the indicated proteins. Data are representative of 3 independent experiments. Blot images were cropped for clarity of presentation. d. MM.1S and MM.1R cells were treated with a titration of dexamethasone for 24 h and cell lysates analysed by Western blotting for the indicated proteins. Data are representative of 3 independent experiments. Blot images were cropped for clarity of presentation